<DOC>
	<DOCNO>NCT00549523</DOCNO>
	<brief_summary>The study 2-stage , double-blind , randomize , placebo-controlled study fifty-six HIV-positive subject randomize first stage . Interim analysis determine continuation stage 2 perform determine continuation 8 subject per arm complete 24-week dose regimen . Primary objective determine safety Lessertia frutescens use HIV-1 infect adult early disease , document impact Lessertia frutescens marker HIV disease progression . Secondary objective determine effect Lessertia frutescens quality life HIV-infected adult length infection .</brief_summary>
	<brief_title>A Controlled Study Safety Efficacy Lessertia Frutescens HIV-infected South African Adults</brief_title>
	<detailed_description>The study 2-stage , double-blind , randomize , placebo-controlled study follow two-stage , statistical selection theory design . Fifty-six HIV positive subject randomize onto Stage 1 comprise 4-arm parallel group ( one placebo 3 treatment group ) trial . One possibly two interim analysis perform determine continuation Stage 2 . A blinded interim analysis determine superior active treatment arm Stage 1 continue Stage 2 8 subject per arm complete 24-week dose regimen interim analysis . The study terminate interim analysis identifies either significant safety issue , demonstrable non-significance . Following significant outcome blind interim analysis , select active placebo control arm continue blind total n=48 participant per arm placebo select treatment group complete 24 week per arm . Respective group receive capsule contain L. frutescens dosages 0 ( placebo material ) , 400mg bid , 800 mg bid 1200 mg bid first stage . Progression stage 2 utilize two arm design 34 subject receive either 0 mg L. frutescens ( placebo ) active dosage L. frutescens bid 24 week . Primary objective determine safety Lessertia frutescens use HIV-1 infect adult early disease , document impact Lessertia frutescens marker HIV disease progression . Secondary objective determine effect Lessertia frutescens quality life HIV-infected adult length infection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Age 21 65 year HIV1 infection document two different rapid test HIV1 antibody CD4 count &gt; 350 cells/ul Viral load &lt; 20,000 copies/mL Normal hematological function Absence clinically significant renal disease Normal liver function Random glucose &lt; 11.1 mmol/L Normal electrocardiogram Regular attendance Wellness Clinic least 4 visit Cognitive capacity sufficient provide inform consent Any AIDSdefining diagnosis Weight loss &gt; 5 % body weight within precede six month Other feature undiagnosed tuberculosis ( include cough , fatigue , drench night sweat abnormal chest radiograph ) Any significant disease ( active TB , hypertension , diabetes mellitus endocrine disorder , peptic ulcer disease , gastrointestinal malabsorption , psychiatric illness ) either newly diagnose control medication . Use allopathic traditional medicine isoniazid TB prophylaxis . Prior current use antiretroviral therapy History allergic condition drug allergy/hypersensitivity Either history family history autoimmune disease Alcohol use &gt; 7 unit per week &gt; 3 per session , tobacco use 10 cigarette per day description recreational drug use within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Alternative Medicine</keyword>
	<keyword>Complementary Medicine</keyword>
</DOC>